 |
|
|
|
September 1999 Cover
|
|
A study published in the Clinical Infectious Diseases
underscores that HIV DNA and protease inhibitor-resistant mutations can emerge in the semen of
patients receiving highly active antiretroviral therapy (HAART) for HIV. Investigators found that 9 percent of HIV-infected men studied had detectable cell-associated HIV
RNA after one month of HAART and that 5 percent had cell-free HIV RNA. In addition, six months after HAART was started, indinavir-resistant mutations were reported
in the seminal leukocytes of one patient, and a patient who had switched to saquinavir displayed protease inhibitor-resistant strains in seminal and blood leukocyte
DNA specimens.
Investigators warn HIV-infected individuals that neither triple combination therapy, nor undetectable levels of HIV load means that one should not avoid
mucosal exposure to HIV-infected semen.
Editor's Note: from Reuters Health Info Services
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
